Literature DB >> 26179132

Post-operative renal function following nephrectomy as part of en bloc resection of retroperitoneal sarcoma (RPS).

Melissa A Hull1, Andrzej Niemierko2, Alex B Haynes1, Alex Jacobson2, Yen-Lin Chen2, Thomas F DeLaney2, John T Mullen1.   

Abstract

BACKGROUND AND OBJECTIVES: Although resection of RPS with en bloc nephrectomy confers the potential benefit of improved locoregional tumor control, little has been published about the long-term post-operative renal function of these patients.
METHODS: Retrospective review of 54 patients undergoing nephrectomy for RPS was performed. Clinicopathologic and treatment characteristics, pre- and post-operative creatinine (Cr) values, and estimated glomerular filtration rates (eGFR) were recorded. The primary outcome measure was progression of chronic kidney disease (CKD) stage.
RESULTS: Median preoperative eGFR was 85 ml/min. Post-nephrectomy, median nadir eGFR was 44 ml/min, rebounding to 62 ml/min at median follow-up of 50 months. Of 49 patients with preoperative eGFR ≥60 ml/min (CKD stage 1,2), 51% preserved eGFR ≥60 postoperatively, whereas 49% progressed to CKD stage 3 (eGFR 30-59). Independent risk factors for progression of CKD stage were age and preoperative eGFR. Eleven patients died of recurrent disease, whereas no patient died of end stage renal disease (ESRD) or required dialysis.
CONCLUSIONS: Although progression of CKD stage occurs in nearly one-half of patients followed for more than 4 years after nephrectomy for RPS, no patient progressed to ESRD or had a limitation in systemic therapy options, even with progression to CKD stage 3.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  chronic kidney disease; nephrectomy; renal function; retroperitoneal sarcoma

Mesh:

Substances:

Year:  2015        PMID: 26179132     DOI: 10.1002/jso.23949

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

Review 1.  [Intra-abdominal and retroperitoneal sarcomas].

Authors:  J Kirchberg; J Weitz
Journal:  Chirurg       Date:  2016-03       Impact factor: 0.955

Review 2.  Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group.

Authors:  William W Tseng; Carol J Swallow; Dirk C Strauss; Sylvie Bonvalot; Piotr Rutkowski; Samuel J Ford; Ricardo J Gonzalez; Rebecca A Gladdy; David E Gyorki; Mark Fairweather; Kyo Won Lee; Markus Albertsmeier; Winan J van Houdt; Magalie Fau; Carolyn Nessim; Giovanni Grignani; Kenneth Cardona; Vittorio Quagliuolo; Valerie Grignol; Jeffrey M Farma; Elisabetta Pennacchioli; Marco Fiore; Andrew Hayes; Dimitri Tzanis; Jacek Skoczylas; Max L Almond; John E Mullinax; Wendy Johnston; Hayden Snow; Rick L Haas; Dario Callegaro; Myles J Smith; Toufik Bouhadiba; Anant Desai; Rachel Voss; Roberta Sanfilippo; Robin L Jones; Elizabeth H Baldini; Andrew J Wagner; Charles N Catton; Silvia Stacchiotti; Khin Thway; Christina L Roland; Chandrajit P Raut; Alessandro Gronchi
Journal:  Ann Surg Oncol       Date:  2022-06-29       Impact factor: 4.339

3.  A Prospective Observational Study of Multivisceral Resection for Retroperitoneal Sarcoma: Clinical and Patient-Reported Outcomes 1 Year After Surgery.

Authors:  Marco Fiore; Cinzia Brunelli; Rosalba Miceli; Michele Manara; Susanna Lenna; Nicolò N Rampello; Dario Callegaro; Chiara Colombo; Stefano Radaelli; Sandro Pasquali; Augusto T Caraceni; Alessandro Gronchi
Journal:  Ann Surg Oncol       Date:  2020-11-11       Impact factor: 5.344

4.  Anterior Approach to En Bloc Resection in Left-Sided Retroperitoneal Sarcoma with Adjacent Organ Involvement: A Study of 25 Patients in a Single Center.

Authors:  Zhen Wang; Jian-Hui Wu; Ang Lv; Cheng-Peng Li; Xiu-Yun Tian; Chun-Yi Hao
Journal:  Med Sci Monit       Date:  2018-02-16

Review 5.  Surgical Principles of Primary Retroperitoneal Sarcoma in the Era of Personalized Treatment: A Review of the Frontline Extended Surgery.

Authors:  Paula Munoz; Pedro Bretcha-Boix; Vicente Artigas; José Manuel Asencio
Journal:  Cancers (Basel)       Date:  2022-08-24       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.